Literature DB >> 14557640

A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Chantal Combredet1, Valérie Labrousse, Lucile Mollet, Clarisse Lorin, Frédéric Delebecque, Bruno Hurtrel, Harold McClure, Mark B Feinberg, Michel Brahic, Frédéric Tangy.   

Abstract

Live attenuated RNA viruses make highly efficient vaccines. Among them, measles virus (MV) vaccine has been given to a very large number of children and has been shown to be highly efficacious and safe. Therefore, this vaccine might be a very promising vector to immunize children against both measles and other infectious agents, such as human immunodeficiency virus. A vector was previously derived from the Edmonston B strain of MV, a vaccine strain abandoned 25 years ago. Sequence analysis revealed that the genome of this vector diverges from Edmonston B by 10 amino acid substitutions not related to any Edmonston subgroup. Here we describe an infectious cDNA for the Schwarz/Moraten strain, a widely used MV vaccine. This cDNA was constructed from a batch of commercial vaccine. The extremities of the cDNA were engineered in order to maximize virus yield during rescue. A previously described helper cell-based rescue system was adapted by cocultivating transfected cells on primary chicken embryo fibroblasts, the cells used to produce the Schwarz/Moraten vaccine. After two passages the sequence of the rescued virus was identical to that of the cDNA and of the published Schwarz/Moraten sequence. Two additional transcription units were introduced in the cDNA for cloning foreign genetic material. The immunogenicity of rescued virus was studied in macaques and in mice transgenic for the CD46 MV receptor. Antibody titers and T-cell responses (ELISpot) in animals inoculated with low doses of rescued virus were identical to those obtained with commercial Schwarz MV vaccine. In contrast, the immunogenicity of the previously described Edmonston B strain-derived MV clone was much lower. This new molecular clone will allow for the production of MV vaccine without having to rely on seed stocks. The additional transcription units allow expressing heterologous antigens, thereby providing polyvalent vaccines based on an approved, safe, and efficient MV vaccine strain that is used worldwide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557640      PMCID: PMC229349          DOI: 10.1128/jvi.77.21.11546-11554.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Reverse Genetics Meets the Nonsegmented Negative-Strand RNA Viruses.

Authors: 
Journal:  Rev Med Virol       Date:  1997-04       Impact factor: 6.989

3.  A recombinant measles virus expressing biologically active human interleukin-12.

Authors:  M Singh; M A Billeter
Journal:  J Gen Virol       Date:  1999-01       Impact factor: 3.891

4.  Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production.

Authors:  D Naniche; A Yeh; D Eto; M Manchester; R M Friedman; M B Oldstone
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Engineering poliovirus as a vaccine vector for the expression of diverse antigens.

Authors:  R Andino; D Silvera; S D Suggett; P L Achacoso; C J Miller; D Baltimore; M B Feinberg
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

7.  Infection of chicken embryonic fibroblasts by measles virus: adaptation at the virus entry level.

Authors:  C Escoffier; D Gerlier
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Sendai virus C proteins counteract the interferon-mediated induction of an antiviral state.

Authors:  D Garcin; P Latorre; D Kolakofsky
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Chimeric measles viruses with a foreign envelope.

Authors:  P Spielhofer; T Bächi; T Fehr; G Christiansen; R Cattaneo; K Kaelin; M A Billeter; H Y Naim
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

10.  Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus.

Authors:  F Kobune; H Sakata; A Sugiura
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

View more
  58 in total

1.  Selection of a peptide mimicking neutralization epitope of hepatitis E virus with phage peptide display technology.

Authors:  Ying Gu; Jun Zhang; Ying-Bing Wang; Shao-Wei Li; Hai-Jie Yang; Wen-Xin Luo; Ning-Shao Xia
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

Review 2.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

3.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

4.  p53 regulates CD46 expression and measles virus infection in myeloma cells.

Authors:  Anne Lok; Geraldine Descamps; Benoit Tessoulin; David Chiron; Marion Eveillard; Catherine Godon; Yannick Le Bris; Astrid Vabret; Celine Bellanger; Laurent Maillet; Sophie Barillé-Nion; Marc Gregoire; Jean-François Fonteneau; Steven Le Gouill; Philippe Moreau; Frederic Tangy; Martine Amiot; Agnes Moreau-Aubry; Catherine Pellat-Deceunynck
Journal:  Blood Adv       Date:  2018-12-11

Review 5.  Paramyxovirus disruption of interferon signal transduction: STATus report.

Authors:  Aparna Ramachandran; Curt M Horvath
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

6.  Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses.

Authors:  Anastassia V Komarova; Chantal Combredet; Laurène Meyniel-Schicklin; Manuel Chapelle; Grégory Caignard; Jean-Michel Camadro; Vincent Lotteau; Pierre-Olivier Vidalain; Frédéric Tangy
Journal:  Mol Cell Proteomics       Date:  2011-09-12       Impact factor: 5.911

7.  Attenuated MuV-S79 as vector stably expressing foreign gene.

Authors:  Duo Zhou; Meng-Ying Zhu; Yi-Long Wang; Xiao-Qiang Hao; Dong-Ming Zhou; Rong-Xian Liu; Chu-Di Zhang; Chu-Fan Qu; Zheng-Yan Zhao
Journal:  World J Pediatr       Date:  2019-08-03       Impact factor: 2.764

8.  An immune competent mouse model for the characterization of recombinant measles vaccines.

Authors:  René R Marty; Marlyse C Knuchel; Teldja Neige Azzouz Morin; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 9.  Measles virus.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor.

Authors:  Grégory Caignard; Anastassia V Komarova; Mehdi Bouraï; Thomas Mourez; Yves Jacob; Louis M Jones; Flore Rozenberg; Astrid Vabret; François Freymuth; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.